Cannabidiol
10 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Cannabidiol for drug resistant epilepsy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cannabidiol for epilepsies, myoclonic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Cannabidiol for epilepsy | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Cannabidiol for epilepsy, absence | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Cannabidiol for lennox gastaut syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Cannabidiol for liver cirrhosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cannabidiol for marijuana abuse | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Cannabidiol for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Cannabidiol for seizures | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Cannabidiol for spasms, infantile | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |